Duralast (dapoxetine)
Duralast is a dapoxetine tablet for premature ejaculation sold in Indian pharmacies by Sun Pharma. See strengths and cautions.
- Active ingredient
- Dapoxetine
- Form
- Tablet
- Company
- Sun Pharma (formerly Ranbaxy Laboratories)
Duralast is a dapoxetine tablet associated with Ranbaxy/Sun Pharma in the cited Indian pharmacy records. Separate 30 and 60 mg listings establish the range reviewed here; they do not establish present stock or a worldwide prescribing indication.
A PE comparison, not an ED upgrade
Dapoxetine research measures ejaculation control, distress and satisfaction alongside timing. A larger listed amount should not be assumed to provide a proportionate increase in benefit. The ingredient article shows the trial averages beside placebo and the tolerability tradeoffs.
Priligy supplies a separate Australian reference record. Similar component amounts do not transfer that authorization or sponsor role to Duralast. The local leaflet and clinical assessment remain product- and market-specific.
Why the medicine list matters
Other antidepressants and serotonergic medicines, alcohol and a tendency to dizziness or fainting can affect suitability. Duralast’s standalone composition also differs from a combined ED/PE tablet. A person seeking ejaculation control should not assume that adding a PDE5 ingredient is necessary simply because combination products appear beside it in a directory.
Product record
- Company
- Sun Pharma (formerly Ranbaxy Laboratories)
- Strengths listed
- Dapoxetine 30 and 60 mg
- Treatment area
- Premature ejaculation (PE)
- Where we found it
- We found it listed by Indian online pharmacy databases (PharmEasy, Practo and Apollo Pharmacy) in October 2026. The database entry does not establish current stock.
- Record reviewed
- 4 October 2026; source retrieval dates are retained with the evidence
Listed strengths identify a product; they are not dosing advice. A listing in one country does not show that a product is authorized where you live.
About dapoxetine
Dapoxetine has defined regional PE indications and on-demand trial evidence. Control and distress matter as well as measured minutes. Fainting, alcohol and interacting medicines need review; standalone evidence does not validate every ED/PE combination.
About Indian brands
Indian-company brands have different retail and catalogue evidence. A pharmacy database entry does not establish current stock, and absence from a checked database does not prove export-only manufacture. Company association, exact product identity and local authorization are separate questions.
Sources
3 sources
Checked .
- Duralast 30 MG Tablet (pack of 4) — PharmEasy (India)
- Duralast 60 MG Tablet (pack of 4) — PharmEasy (India)
- Priligy (dapoxetine 30 mg) Australian register entry — Therapeutic Goods Administration (Australia). Ingredient reference; it does not describe this brand.